THEMA US1420381089

Sie befinden sich hier: Startseite > Themen > US1420381089?lang=en

Thema: US1420381089

CRBU, US1420381089

Caribou Biosciences stock: ASH presentations follow CAR-T shutdown

Caribou Biosciences stock draws attention after three ASH 2026 presentations were accepted. The abstracts predate plans to end both allogeneic CAR-T programs.

ad-hoc-news.de, vor 40 Minuten

CRBU, US1420381089

Caribou Biosciences reviews options. Caribou Biosciences ...

Caribou halted two CAR-T programs and began a review on October 6, 2026. Market value for Caribou Biosciences stock stood at USD 55.6 million.

ad-hoc-news.de, 21.10.26 05:40 Uhr

CRBU, US1420381089

Wall Street Zen downgrades Caribou Biosciences stock to ...

Wall Street Zen moved Caribou from Hold to Sell on September 19, 2026. The USD 7.75 consensus target covers Caribou Biosciences stock.

ad-hoc-news.de, 05.10.26 18:13 Uhr

CRBU, US1420381089

Caribou Biosciences stock draws a Moderate Buy consensus ...

Five analysts set a Moderate Buy consensus and a USD 7.75 average target for Caribou Biosciences stock. Q2 EPS beat estimates, while revenue missed.

ad-hoc-news.de, 05.10.26 11:15 Uhr

CRBU, US1420381089

Caribou Biosciences stock draws a Moderate Buy consensus ...

Bank of America reported 1.41 million CRBU shares in a Q2 filing dated October 1, 2026. Five analysts set a USD 7.75 average target against a USD 1.22 close.

ad-hoc-news.de, 04.10.26 19:03 Uhr

CRBU, US1420381089

Caribou Biosciences Stock - Long-term CRISPR strategy in ...

Caribou Biosciences pursues an allogeneic CAR-T and genome-editing strategy in oncology. With no fresh corporate headlines today the spotlight shifts to its long-term business ...

ad-hoc-news.de, 20.06.26 19:48 Uhr

CRBU, US1420381089

Caribou Biosciences Stock - Weekly review and sector backdrop ...

Caribou Biosciences stock gets a Friday checkup with a focus on this week’s moves the broader gene-editing sector and what the current analyst consensus signals for the ...

ad-hoc-news.de, 19.06.26 19:00 Uhr

CRBU, US1420381089

Caribou Biosciences stock (US1420381089): Q1 loss narrows ...

Caribou Biosciences has reported a smaller quarterly loss while continuing to invest in its CRISPR-based cell therapy pipeline. What the latest Q1 2026 figures and the stock’s ...

ad-hoc-news.de, 21.05.26 22:33 Uhr

CRBU, US1420381089

Caribou Biosciences stock (US1420381089): Q1 update and ...

Caribou Biosciences reported first-quarter 2026 results on May 7 including EPS of -$0.26 versus estimates of -$0.33. The company’s CRISPR-based pipeline and Nasdaq-listed ...

ad-hoc-news.de, 19.05.26 22:29 Uhr

CRBU, US1420381089

Caribou Biosciences stock (US1420381089): fresh data from ...

Caribou Biosciences has reported new clinical data on its lead off?the?shelf CAR?T candidate for lymphoma drawing renewed attention to the small?cap gene?editing player. What ...

ad-hoc-news.de, 16.05.26 20:45 Uhr